Skip to main content
2025 Annual Convention & Scientific Sessions Main banner

Concurrent Session-Banyan 1

Alzheimer's Diseases – The Newest Medications 

Thursday, October 9, 2025
2:30 PM - 3:15 PM East Coast USA Time
Location: Banyan 1
Disclosure(s):
Steven T. Dinsmore, DO, FACOI: No financial relationships to disclose
Dominic F. Glorioso, DO, PhD, FACOI, FAAHPM, HMD, Jr.: No financial relationships to disclose
Espay AJ, Kepp KP, Herrup K. Lecanemab and Donanemab as Therapies for Alzheimer’s Disease: An Illustrated Perspective on the Data. eNeuro. 2024;11(7):ENEURO.0319-23.2024. doi:10.1523/ENEURO.0319-23.2024

Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239

van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388:9–21. doi:10.1056/NEJMoa2212948

Learning Objectives:

  • Analyze the multifactorial nature of Alzheimer’s disease by evaluating the debated underlying drivers—including amyloid, tau, neuroinflammation, vascular, and metabolic co-pathologies—in order to explain why monoclonal antibody–based amyloid clearance alone is insufficient and why future therapeutic strategies will likely require multi-target approaches.
  • Evaluate the development and FDA approval of lecanemab and donanemab by analyzing how clinical efficacy endpoints and biomarker validation—such as slowed cognitive decline, PET-detected amyloid clearance, and downstream biomarker changes—converge to support regulatory decisions for disease-modifying therapies.
  • Apply knowledge of eligibility criteria, dosing regimens, monitoring protocols, and risk–benefit considerations—including ARIA management and mandatory MRI surveillance—to safely implement anti-amyloid therapies for patients with early, biomarker-confirmed Alzheimer’s disease in clinical practice.